FEATURES OF THE EFFECT OF TRIMETAZIDINE ON THE INDICATORS OF INFLAMMATION AND FIBROSIS IN PATIENTS WITH STABLE CORONARY ARTERY DISEASE WITH CONCOMITANT NON-ALCOHOLIC FATTY LIVER DISEASE

Authors:

Abstract:

The issue of finding ways to optimize the treatment of patients with stable coronary artery disease in combination with non-alcoholic fatty liver disease is very relevant today. The aim of this study was to evaluate the effectiveness of drug therapy for coronary artery disease in combination with non-alcoholic fatty liver disease using trimetazidine, taking into account the effect on components of the low-intensity systemic inflammatory response, as well as the progression of fibrosis and steatosis. The study involved patients with combined pathology who, depending on the treatment they received, were divided into two groups. All patients underwent anamnestic, clinical, anthropometric, instrumental (abdominal ultrasound), and laboratory tests (complete blood count with leukocyte indices, determination of levels of high-sensitivity C-reactive protein, matrix metalloproteinase-6, galectin-3, and monocyte chemotactic protein-1). Patients in the second group received trimetazidine for one month. The use of trimetazidine improved exercise tolerance, slowed the progression of fibrosis and steatosis, reduced body mass index, and reduced the intensity of the systemic inflammatory response.

Keywords:

stable coronary artery disease non-alcoholic fatty liver disease trimetazidine inflammation liver fibrosis

References:

1. Borges-Canha M, Neves JS, Libânio D, Von-Hafe M, Vale C, Araújo-Martins M, et al. Association between nonalcoholic fatty liver disease and cardiac function and structure—a meta-analysis. Endocrine. 2019 Dec 3;66(3):467–76. DOI:10.1007/s12020-019-02070-0.
2. Brunt EM. Nonalcoholic Steatohepatitis: Definition and Pathology. Semin Liver Dis. 2001;21(01):003–16. DOI:10.1055/s-2001-12925.
3. Budzianowski J, Pieszko K, Burchardt P, Rzeźniczak J, Hiczkiewicz J. The Role of Hematological Indices in Patients with Acute Coronary Syndrome. Dis Markers. 2017;2017. DOI:10.1155/2017/3041565.
4. Eslam M, Newsome PN, Sarin SK, Anstee QM, Targher G, Romero-Gomez M, et al. A new definition for metabolic dysfunction-associated fatty liver disease: An international expert consensus statement. J Hepatol. 2020 Jul;73(1):202–9. DOI:10.1016/j.jhep.2020.03.039.
5. Gusev E, Sarapultsev A. Atherosclerosis and Inflammation: Insights from the Theory of General Pathological Processes. Int J Mol Sci. 2023 Apr 26;24(9):7910. DOI:10.3390/ijms24097910.
6. Heyens LJM, Busschots D, Koek GH, Robaeys G, Francque S. Liver Fibrosis in Non-alcoholic Fatty Liver Disease: From Liver Biopsy to Non-invasive Biomarkers in Diagnosis and Treatment. Front Med (Lausanne) [Internet]. 2021 Apr;8. DOI:10.3389/fmed.2021.615978 Available from: http://dx.doi.org/10.3389/fmed.2021.615978.
7. Higashiura Y, Furuhashi M, Tanaka M, Takahashi S, Mori K, Miyamori D, et al. Elevated Fatty Liver Index Is Independently Associated With New Onset of Hypertension During a 10‐Year Period in Both Male and Female Subjects. J Am Heart Assoc. 2021 Jul 20;10(14). DOI:10.1161/JAHA.121.021430.
8. Mero Ríos A, Morán Pinzón JA, Ordoñez C, Guerrero de León E. The Antioxidant Properties and Cardiovascular, Antidiabetic, and Renal Effects of Trimetazidine Described in Research on Experimental Models. Current Reviews in Clinical and Experimental Pharmacology. 2024 Aug 20;19. DOI:10.2174/0127724328303999240607072031.
9. Singh D, Oladimeji-Salami J, Akindele AJ. New insights on pharmacological and therapeutic potentials of trimetazidine beyond anti-anginal drug: A comprehensive review. Eur J Pharmacol. 2024 Dec;985:177062. DOI:10.1016/j.ejphar.2024.177062.
10. Wang Z, Wang Y, Luo F, Zhai Y, Li J, Chen Y, et al. Impact of advanced liver fibrosis on atrial fibrillation recurrence after ablation in non-alcoholic fatty liver disease patients. Front Cardiovasc Med [Internet]. 2022 Oct 6 [cited 2023 Feb 2];9. DOI:10.3389/FCVM.2022.960259/FULL.
11. Younes R, Caviglia GP, Govaere O, Rosso C, Armandi A, Sanavia T, et al. Long-term outcomes and predictive ability of non-invasive scoring systems in patients with non-alcoholic fatty liver disease. J Hepatol. 2021 Oct;75(4):786–94. DOI:10.1016/j.jhep.2021.05.008.
12. Yuan M, Ren F, Gao D. The Value of SII in Predicting the Mortality of Patients with Heart Failure. Dis Markers [Internet]. 2022 [cited 2023 Dec 22];2022. DOI:10.1155/2022/3455372 Available from: https://pubmed.ncbi.nlm.nih.gov/35634435.
13. Zhang Y, Li C, Li X, Wu C, Zhou H, Lu S, et al. Trimetazidine improves hepatic lipogenesis and steatosis in non alcoholic fatty liver disease via AMPK ChREBP pathway. Mol Med Rep. 2020 Sep;22(3):2174–82. DOI:10.3892/mmr.2020.11309.

Publication:

«World of Medicine and Biology» Vol. 21 No. 92 (2025) , с. 136-141
УДК 616.36-003.826+616.125-008.313

DOI:

https://doi.org/10.26724/2079-8334-2025-2-92-136-141